Navigation Links
Vaccine targeting latent TB enters clinical testing
Date:12/1/2011

COPENHAGEN, DENMARK/ROCKVILLE, MD, USA Statens Serum Institut and Aeras today announce the initiation of the first Phase I clinical trial of a new candidate TB vaccine designed to protect people latently infected with TB from developing active TB disease. The trial is being conducted by the South African Tuberculosis Vaccine Initiative (SATVI) at its field site in Worcester, in the Western Cape province of South Africa. Dr. Hassan Mahomed is the principal investigator.

"Two billion men, women and children live with latent TB infection," said Jim Connolly, President and Chief Executive Officer of Aeras. "It's daunting to comprehend that there is a vast reservoir of people with a 5-10% lifetime risk of becoming sick with TB. A vaccine that prevents TB disease in this population could save millions of lives, and this trial is a first step in assessing a vaccine candidate designed for this purpose."

The candidate TB vaccine (SSI H56-IC31) is a subunit vaccine containing recombinant TB proteins formulated in a proprietary adjuvant IC31 from Intercell. It is being developed under a consortium of researchers led by Peter Andersen at the Statens Serum Institut (SSI) based in Copenhagen. The consortium is supported as part of the Grand Challenges in Global Health, an initiative that fosters scientific breakthroughs needed to prevent, treat and cure diseases of the developing world.

"The development of urgently needed new TB vaccines requires a global effort," said Prof. Peter Andersen, the Vice President of Vaccine Research & Development at SSI. "The advancement of this candidate from an idea to the clinic working in collaboration first with the Grand Challenges consortium and now with Aeras and SATVI is an important and exciting milestone for all the researchers involved."

This clinical trial will be the first to test this vaccine candidate in people. It will assess the safety and immunogenicity of SSI H56-IC31 in 25 adults,
'/>"/>

Contact: Annmarie Leadman
aleadman@aeras.org
240-599-3018
Aeras
Source:Eurekalert

Page: 1 2

Related biology news :

1. BWH researchers develop a vaccine prototype stronger than traditional vaccines
2. Award-winning research points toward Alzheimer’s vaccine
3. 21st century vaccines -- innovation in design and rational use
4. Newly identified antibodies may improve pneumonia vaccine design
5. TB vaccine candidate shows early promise
6. Scripps Research scientists create vaccine against heroin high
7. Promising developments in vaccine research, development of a vaginal gel and PrEP lead to calls for a combination of biomedical and non biomedical approaches to HIV prevention policy
8. Discovery of natural antibody brings a universal flu vaccine a step closer
9. Innovative vaccines with nanotechnology
10. Adjuvant combo shows potential for universal influenza vaccine
11. Study shows the HPV vaccine Gardasil doesnt increase disease activity in SLE patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... of bacterial infections, including MRSA and MSSA could ... bumps that mimic the scaly surface of shark ... access journal Antimicrobial Resistance and Infection Control ... materials prevented the spread of human disease bacteria ... Sharklet, is an arrangement of ridges formulated to ...
(Date:9/16/2014)... Ohio (September 17, 2014)The North American Menopause Society ... the comprehensive care of midlife womenon everything from ... "The North American Menopause Society Recommendations for Clinical ... in the Society,s journal Menopause . This ... for the care of midlife women freely available ...
(Date:9/16/2014)... Fire began on September 13, 2014. The fire is ... currently over 2,300 acres in size and is mostly ... Fire was calm Monday night due to higher humidity. ... point and beginning to construct a fireline on the West ... are working on the fire: , 7 20-person Crews, 4 ...
Breaking Biology News(10 mins):Sharks' skin has teeth in the fight against hospital superbugs 2
... UT Southwestern Medical Center researchers have identified compounds ... disease, a finding that may eventually lead to a ... degenerative nerve disorders. "Our studies have uncovered a ... for other neurodegenerative diseases," said Dr. Ilya Bezprozvanny, professor ...
... A new study conducted by a team of ... light on a possible new approach to treat the ... enzyme that connects extracellular fibers. The study, published online ... the direction of Katya Ravid, PhD, professor of medicine ...
... MARC (Minority Access to Research Careers) Program has announced the ... of Reproduction (SSR) Annual Meeting in Portland, Oregon from July ... to promote the entry of underrepresented minority students, postdoctorates and ... to encourage the participation of young scientists at the 2011 ...
Cached Biology News:Compound may provide drug therapy approach for Huntington's disease 2BUSM study identifies new potential approaches to treat myelofibrosis 2
(Date:9/18/2014)... San Diego, CA (PRWEB) September 18, 2014 ... promotions which include Sartorius/Biohit, Socorex, Capp, and ... working with volumes of 100 uL or less ... pharmaceutical, oncology, and forensic applications. , The ... of high quality and economic alternative products to ...
(Date:9/17/2014)... INCLINE VILLAGE, Nev. , Sept. 17, 2014  PDL ... notified by its independent registered accounting firm, Ernst & Young ... The resignation was confirmed in a letter delivered to the ... 8-K filed on September 16, 2014.  PDL ... "We have received a number of inquiries on ...
(Date:9/17/2014)... SEATTLE, WA , Sept. 17, 2014 /PRNewswire/ - ... that it intends to offer and sell shares of ... in separate but concurrent underwritten public offerings.  The Series ... shares of Oncothyreon Common Stock, provided that conversion will ... its affiliates would beneficially own more than 4.99% of ...
(Date:9/17/2014)... COLUMBIA, Md. (PRWEB) September 17, 2014 ... Nexera-e Comprehensive Two-Dimensional Liquid Chromatograph (2D-LC), which ... most complex sample matrices. The system provides ... of sample analytes, which is beneficial to ... food extracts, and natural products. , Comprehensive ...
Breaking Biology Technology:Major Pipette Distributor Pipette.com Announces Promotions on Sartorius/Biohit, Socorex, Capp, and AccuPet Micropipettes 2Major Pipette Distributor Pipette.com Announces Promotions on Sartorius/Biohit, Socorex, Capp, and AccuPet Micropipettes 3PDL BioPharma Issues Statement on Resignation of Ernst and Young as Corporate Auditors 2PDL BioPharma Issues Statement on Resignation of Ernst and Young as Corporate Auditors 3Oncothyreon Announces Proposed Public Offerings 2Shimadzu’s New Nexera-e Two Dimensional Comprehensive Liquid Chromatograph Empowers Laboratories to Separate Even the Most Complex Mixtures 2
... 5, 2011 TetraLogic Pharmaceuticals , a biopharmaceutical ... treat cancer, today announced the initiation of a Phase ... candidate, TL32711, in elderly patients with acute myelogenous leukemia ... Hospital of the University of Pennsylvania and is an ...
... FRANCISCO, Calif., Dec. 5, 2011 diaDexus, Inc. (OTC ... focused on the development and commercialization of patent-protected ... cardiovascular disease, today said that it plans to present ... Metabolic Disorders Conference on Tuesday, December 6, 2010 at ...
... Corp. announced today that Wayne R. Gombotz, Ph.D. has ... Officer.  Dr. Gombotz brings a significant amount of ... at Immune Design.  He will oversee product development ... candidates. (Logo: http://photos.prnewswire.com/prnh/20111018/SF88252LOGO ...
Cached Biology Technology:TetraLogic Pharmaceuticals Announces Initiation of a Phase 1/2 Clinical Trial of TL32711 in Patients with Acute Myelogenous Leukemia (AML) 2TetraLogic Pharmaceuticals Announces Initiation of a Phase 1/2 Clinical Trial of TL32711 in Patients with Acute Myelogenous Leukemia (AML) 3Immune Design Corp. Appoints Wayne R. Gombotz, Ph.D. as Chief Development Officer 2
... were designed for full-length gene cloning and ... identify the desired cDNA clone. The first ... "Master Plate," where each well contains plasmid ... positive well(s) by gel electrophoresis of the ...
... The Rapid-Screen cDNA Library Panels were ... just three sets of PCRs to identify ... analysis is performed in a 96-well "Master ... from 5,000 clones. Having identified the positive ...
... The DSQ II (Dual-Stage Quadrupole) ... the world leader in analytical instrumentation, introduces ... the DSQ II. Based on the ... DSQ and PolarisQ GC/MS systems, the DSQ ...
... Panels were designed for full-length gene cloning ... to identify the desired cDNA clone. The ... 96-well "Master Plate," where each well contains ... the positive well(s) by gel electrophoresis of ...
Biology Products: